Effect of Renal Impairment on Pharmacokinetics and Safety of Ensitrelvir, a SARS-CoV-2 3CL Protease Inhibitor

Takayuki Katsube,Safwan Kezbor,Ryosuke Shimizu,Ryuji Kubota
DOI: https://doi.org/10.1007/s40121-024-00946-x
2024-03-12
Infectious Diseases and Therapy
Abstract:Ensitrelvir, a novel oral inhibitor of 3C-like protease of SARS-CoV-2, shows efficacy and safety in participants with mild to moderate COVID-19. Since urinary recovery of ensitrelvir ranged from 12.9% to 21.8% across dose groups given 20–1000 mg in a single-ascending dose study, renal excretion contributes to the elimination of ensitrelvir. Therefore, the effect of renal impairment on the pharmacokinetics and safety of ensitrelvir needed to be evaluated.
infectious diseases
What problem does this paper attempt to address?